Calcitonin oral - Enteris BioPharma
Alternative Names: Calcitonin-salmon [rDNA origin] delayed release tablets; Oral recombinant salmon calcitonin - Tarsa Therapeutics; Ostora; rsCT; Salmon calcitonin oral - Tarsa Therapeutics; sCT oral; TBRIALatest Information Update: 25 Sep 2021
At a glance
- Originator Unigene Laboratories
- Developer Enteris BioPharma; R-Pharm; Tarsa Therapeutics
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Postmenopausal osteoporosis
- No development reported Osteoarthritis
Most Recent Events
- 09 Apr 2021 No development reported - Preregistration for Postmenopausal osteoporosis in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis(Combination therapy) in USA (PO)
- 19 Oct 2015 Planned Prescription Drug User Fee Act (PDUFA) date for Postmenopausal osteoporosis in USA (PO) is 2016-05-30